Intellihealth Launches Evolve Mobile 3.0

Intellihealth, a leading health-tech software and clinical services company that delivers a comprehensive and clinically proven medical model for treating obesity, has introduced version 3.0 of Evolve Mobile, the patient-side mobile app companion to the Evolve software-as-a-service platform for healthcare providers.

Intellihealth’s EvolveTM is a turnkey medical obesity treatment solution that easily integrates into any practice and streamlines all aspects of care, including assessment, diagnosis, prescription and treatment. Patients’ individualized treatment plans — addressing diet, behavior and psychology, as well as pharmacotherapy when appropriate — are developed and continually refined by expert obesity clinicians based on factors such as their medical history and health risks, electronic health record information, data from wearables and connected devices, and learning center progress.

Evolve Mobile 3.0 includes two significant new features: medication monitoring, which enables patients to set up personalized reminders to take their anti-obesity medications regularly and allows both patients and providers to monitor patterns to make sure prescriptions are being followed; and Apple Health and Google Fit integration, which supports seamless access to weight, blood pressure and heart-rate data from connected devices. Together, these tools offer patients and providers a more comprehensive view of overall health and program compliance over time. The upgrade also incorporates a range of performance improvements and updates throughout the app.

“Remote medication monitoring can improve the efficacy of treatment for many chronic diseases, and obesity is no exception,” said Venky Surya, CPTO at Intellihealth. “With Evolve Mobile 3.0, care teams can better monitor their patients’ medication usage as well as a variety of critical indicators, allowing them to closely track patients’ overall health and weight-loss progress and respond quickly when individualized treatment plans need to be adjusted. This reinforces positive messaging and leads to better patient engagement in our programs.”

The new features extend the app’s existing capabilities, which include meal planning tailored to individual dietary preferences; easy food, weight and activity logging; regular virtual visits and messaging with care team members; and educational resources and other tools to support engagement.

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.